US FDA To Rely On Inspections From More European Countries
Executive Summary
The US Food and Drug Administration can now rely on the results of GMP inspections from 20 EU member states after confirming that five more countries have been deemed suitable for inclusion in its mutual recognition agreement with the EU.
You may also be interested in...
US FDA's Brexit: One Staffer Moving, But Impact Still May Loom Large
Uncertainty about Brexit's impact on the FDA-EMA mutual recognition agreement are among issues worrying regulators as countdown continues to the UK's departure from the EU.
EMA Reports Sharp Reduction In EU GMP Inspections Last Year
EU health authorities inspected fewer drug manufacturing facilities under Europe’s centralized procedure in 2017 thanks to last year’s US/EU mutual recognition agreement, according to a 2017 annual report from the European Medicines Agency. They also found fewer GMP problems at the facilities they did inspect.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.